2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Sunday, November 10, 2019

9:00AM-11:00AM: Abstract Number: 209

Joint Overuse in Patients with Rheumatoid Arthritis

Epidemiology & Public Health Poster I: RA – ARP

9:00AM-11:00AM: Abstract Number: 46

Key Inflammatory Biomarkers at Baseline Are Associated with Filgotinib Response at Week 12 in Rheumatoid Arthritis Patients with Inadequate Response or Intolerance to Biologic DMARDs

RA – Etiology & Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 87

KINE-101, a Novel Synthetic Peptide with Potent Regulatory T Cells Activation to Treat Rheumatoid Arthritis

T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 668

Lack of Uptake of Prophylactic Human Papilloma Virus (HPV) Vaccination Among Women with Systemic Lupus Erythematosus (SLE) in the Detroit, MI Area, a High Risk Population

SLE – Clinical Poster I: Epidemiology & Pathogenesis

9:00AM-11:00AM: Abstract Number: 268

LARS Study: Latin American Rheumatologist Survey

Health Services Research Poster I – ACR/ARP

9:00AM-11:00AM: Abstract Number: 164

Learner Practice Gaps in Osteoporosis: Piloting a Metabolic Bone Disease Curriculum Within a Fracture Liaison Service Framework

Education Poster

9:00AM-11:00AM: Abstract Number: 74

LILRA3 Promotes Lupus-like Chronic Graft-versus-Host Disease by Expansion of Follicular Helper T Cells and Anti-dsDNA Autoantibodies

SLE – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 41

Liver Dysfunction Associated with Rheumatoid Arthritis: Impact of Obesity and Effects of DMARDs in Hepatic Alterations

RA – Etiology & Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 574

Localization and Morphology of Magnetic Resonance Imaging Features of Pathologic Changes in the Sacroiliac Joints Suggestive of Axial Spondyloarthritis – a Systematic Comparison of Patients and Controls with Chronic Back Pain

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 469

Location and Size of Affected Joints Are Useful to Predict Prognosis of Patients with Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis

9:00AM-11:00AM: Abstract Number: 757

Long-term Clinical Course and Outcomes of 2013 Patients with Takayasu Arteritis

Vasculitis – Non-ANCA-Associated & Related Disorders Poster I: Takayasu's Arteritis & Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 251

Long-term Financial Impact of Switching from Reference to Biosimilar Etanercept When Considering Short-term Formulary Management Costs in the US

Health Services Research Poster I – ACR/ARP

9:00AM-11:00AM: Abstract Number: 376

Long-term Outcome and Prognostic Factors of Patients with Interstitial Pneumonia with Autoimmune Features: A Single Center Large-scale Observational Cohort Study

Miscellaneous Rheumatic & Inflammatory Disease Poster I: Fibroinflammatory & Granulomatous Disorders & Therapies

9:00AM-11:00AM: Abstract Number: 538

Long-Term Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to CsDMARDs: Results at 60 Weeks

RA – Treatments Poster I: Novel Treatments

9:00AM-11:00AM: Abstract Number: 508

Longer Term Safety and Efficacy of Peficitinib in Patients with Rheumatoid Arthritis After 22.7 Months Mean Treatment Exposure: Interim Data from a Long-Term, Open-Label Extension Study in Japan, Korea and Taiwan

RA – Treatments Poster I: Novel Treatments

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].